5432752025-01-012025-03-315432752025-03-315432752024-03-315432752024-04-012025-03-315432752025-01-012025-03-31in-capmkt:OtherExpenses1Member5432752024-04-012025-03-31in-capmkt:OtherExpenses1Member5432752025-01-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15432752025-01-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss25432752024-04-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15432752024-04-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss25432752025-01-012025-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15432752025-01-012025-03-31ItemsThatWillBeReclassifiedToProfitAndLoss25432752024-04-012025-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15432752024-04-012025-03-31ItemsThatWillBeReclassifiedToProfitAndLoss25432752025-01-012025-03-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares543275ANURASNOTLISTEDINE930P01018ANUPAM RASAYAN INDIA LIMITEDMain BoardEquity2024-04-012025-03-312025-05-232025-05-16INRMillionsQuarterlyFourth quarterSingle segmentManufacturing of Industrial Chemicals2025-05-2317:10:002025-05-2317:50:00trueCash Flow IndirectDeclaration of unmodified opinion2025-01-012025-03-31AuditedConsolidated500158000055380000505696000028296900000-454610000184140000312200000306570000997810000417580000088116000008811600001723400007954000025188000006292800000000629280000350800006643600004456700001836100004812500001831100001099310000104.064.06004.064.061 The above Consolidated Financial results for the quarter and year ended March 31 2025 have been prepared by the Company in accordance with Regulation 33 of SEBI Listing Obligations and Disclosure Requirements Regulations 2015 as amended and were reviewed by the Audit Committee of the Board and thereafter were approved and taken on record by the Board of Directors in their meeting held on May 23 2025. <BR> 2 Based on the management approach as defined in Ind AS 108 Operating Segments the Chief Operating Decision Maker CODM evaluates the companys performance and allocates resources based on an analysis of various performance indicators of business segments in which the company operates. <BR> The Company is primarily engaged in the business of custom synthesis and manufacturing of specialty chemicals which the management and CODM recognise as the sole business segment Hence disclosure of segmentwise information is not required and accordingly not provided. <BR> 3 The Company has investment in the following subsidiary companies and an associate company as on March 31, 2025 and accordingly, consolidated financial results for the quarter and year ended on March 31, 2025 includes following entities <BR> Sr. No. Name of the Subsidiary Nature of relationship <BR> a Jainam Intermediates Private Limited Whollyowned subsidiary <BR> b Tanfac Industries Limited Subsidiary Company over which the Company exercises effective control <BR> c ARIL Transmodal Logistic Private Limited Whollyowned subsidiary <BR> d ARIL Fluorospeciality Private Limited Whollyowned subsidiary <BR> e Anupam Japan GK Whollyowned subsidiary <BR> f Anupam Europe AG Whollyowned subsidiary <BR> g Anupam USA LLC Whollyowned subsidiary <BR> h Anupam General Trading FZE Whollyowned subsidiary <BR> i Tangent Science Private Limited An associate Company of wholly owned subsidiary of the Company <BR> 4 The figures for the quarter ended March 31, 2025, and March 31, 2024, are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to Nine months of the relevant financial year which were subjected to limited review. <BR> 5 The figures of the previous period have been regrouped, rearranged and,or recasted wherever considered necessary. 2024-04-012025-03-31AuditedConsolidated143697400001147700001448451000093692200000-332434000073615000011222000001022760000358001000012506000000197851000001978510000438090000-593000003787900000159972000000001599720000119400001611660000933490000666230000942730000668930000109931000010274038200008.58.5008.58.5Other Expenses997810000Other Expenses35800100002038367000021616500001232050000229560000157100001026700001245670000136405000001587510000269584900001451502000069890000733757000011304600001467100002053000020230000872539000039590000245035000025730350000526888400001099310000274038200002850313000023134200003081655000017118100001711810000188900001104930000954610000379024000011466410000897000005674060000576376000030900000017539170000421790000107320000137700001808205000021872290000526888400001134160000-3963530000-19687900000-5100000029243000001723090000000102276000001750000000-7509000004350000760000-51000000-17950000083400000-18520300001264800000004277300000-3012500000000000014600004099190000256395000019607300000000000000044990000000043500000236090000-32990600000031520000000002808650000149030000-328200000134190000105241000004000000002232740000-13675700000-136757000024980300001130460000Gain/(loss) on remeasurements of the defined benefits plan14960000Income tax (expense)/income on remeasurements of the defined benefits plan-53200009640000Gain/(loss) on remeasurements of the defined benefits plan15290000Income tax (expense)/income on remeasurements of the defined benefits plan-48500001044000000Effective portion of gain/(loss) on hedging instruments in a cash flow hedge38740000Income tax (expense)/income on effective portion of gain/(loss) on hedging instruments in a cash flow hedge-1330000025440000Effective portion of gain/(loss) on hedging instruments in a cash flow hedge2470000Income tax (expense)/income on effective portion of gain/(loss) on hedging instruments in a cash flow hedge-9700001500000003508000011940000AuditedtrueM/s. Rajendra & Co.true2027-08-31